FIELD: chemistry.
SUBSTANCE: invention relates to a compound (I), where X is halogen; R1 is selected from H; R2 is selected from a group consisting of H and C1-C4alkyl; or R2 together with R9 and atoms attaching them form a saturated five-member ring; R3 is selected from a group consisting of H and C1-C6alkyl; R4 and R5 independently selected from H; R6 and R7 independently selected from H; R8 and R9 independently selected from a group consisting of H and C1-C6alkyl, or a pharmaceutically acceptable acid addition salt of compound I, a racemic mixture of compound I or a corresponding enantiomer and/or optical isomer of compound I. Invention also relates to a pharmaceutical composition inhibiting PDE1, based on compound I.
EFFECT: obtaining novel compounds and pharmaceutical compositions based on said compounds which can be used in medicine for treating neurodegenerative and psychic disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, depression, attention deficit hyperactivity disorder (ADHD), etc.
13 cl, 1 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDAZOPIRASOTHINES AS PDE1 INHIBITORS | 2016 |
|
RU2712219C2 |
| JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
| USE OF 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | 2017 |
|
RU2759380C2 |
| C-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN CANCER TREATMENT | 2018 |
|
RU2769694C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF ANGIOGENESIS | 2000 |
|
RU2262935C2 |
| THIAZOLPYRIMIDINES | 2012 |
|
RU2610840C2 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
| SUBSTITUTED TRICYCLIC COMPOUNDS | 2020 |
|
RU2827641C1 |
| BICYCLIC KETONES AND METHODS OF THEIR USE | 2018 |
|
RU2797922C2 |
